We are developing dialysis-like therapies to address cardiovascular disease and cancer. Our therapies are designed to improve and extend the quality of patient lives, and their successful clinical advancement may provide strategic value to the dialysis and biopharmaceutical industry.

Sigyn CardioDialysis™ is a first-in-industry medical device to treat cardiovascular disease, the leading cause of death globally. CardioDialysis™ aims to reduce the circulating presence of inflammatory molecules that fuel cardiovascular disease progression while simultaneously lowing levels of cholesterol-transporting lipoproteins that contribute to heart attacks, strokes, and other Major Adverse Cardiovascular Events (MACE). Based on its broad-spectrum mechanism, CardioDialysis™ offers to reduce the incidence of MACE by overcoming the inherent limitations of single-target drugs.

Our cancer therapy development pipeline is comprised of ImmunePrep™ to optimize the delivery of immunotherapeutic antibodies; ChemoPrep™ to enhance the targeted delivery of chemotherapy; and ChemoPure™ to reduce the toxicity of chemotherapy.

To learn more about our endeavors, we encourage you to navigate through our website. Additionally, you can click on the “Investors” button to access our SEC filings and register to receive email news alerts.